Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-106238
Filing Date
2025-08-11
Accepted
2025-08-11 07:34:05
Documents
76
Period of Report
2025-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q kpti-20250630.htm   iXBRL 10-Q 3379376
2 EX-10.1 kpti-ex10_1.htm EX-10.1 33929
3 EX-31.1 kpti-ex31_1.htm EX-31.1 12673
4 EX-31.2 kpti-ex31_2.htm EX-31.2 12762
5 EX-32.1 kpti-ex32_1.htm EX-32.1 8151
6 EX-32.2 kpti-ex32_2.htm EX-32.2 8127
  Complete submission text file 0000950170-25-106238.txt   11258231

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT kpti-20250630.xsd EX-101.SCH 1270785
79 EXTRACTED XBRL INSTANCE DOCUMENT kpti-20250630_htm.xml XML 1949947
Mailing Address 85 WELLS AVENUE SECOND FLOOR NEWTON MA 02459
Business Address 85 WELLS AVENUE SECOND FLOOR NEWTON MA 02459 617-658-0600
Karyopharm Therapeutics Inc. (Filer) CIK: 0001503802 (see all company filings)

EIN.: 263931704 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36167 | Film No.: 251200197
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)